Overview

Apremilast for RAS

Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Determination of treatment efficacy and safety of Apremilast in patients with RAS
Phase:
Early Phase 1
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Celgene
Treatments:
Apremilast
Thalidomide